2-amino-1-(2-trifluoromethyl-phenyl)-ethanone hydrochloride | 111595-55-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-amino-1-(2-trifluoromethyl-phenyl)-ethanone hydrochloride
• 英文别名: 2-amino-2'-(trifluoromethyl)-acetophenone hydrochloride；2-Amino-1-(2-(trifluoromethyl)phenyl)ethanone hydrochloride；2-amino-1-[2-(trifluoromethyl)phenyl]ethanone;hydrochloride
• CAS: 111595-55-2
• 化学式: C₉H₈F₃NO*ClH
• 分子量: 239.625
• InChiKey: ZWPSZPZGWRCFIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.27
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  43.1
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2922399090

文献信息

• Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors
  申请人：Meier Heinrich

  公开号：US20090312381A1

  公开（公告）日：2009-12-17

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新颖的取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产方法，单独或组合使用以治疗和/或预防疾病，以及用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• [EN] ARYL OR HETEROARYL CARBONYL DERIVATIVES DERIVATIVES USEFUL AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS<br/>[FR] DÉRIVÉS ARYLCARBONYLIQUES OU HÉTÉROARYLCARBONYLIQUES UTILES COMME ANTAGONISTES DU RÉCEPTEUR VANILLOÏDE DE TYPE 1 (VR1)
  申请人：PFIZER JAPAN INC

  公开号：WO2006016218A1

  公开（公告）日：2006-02-16

  This invention provides a compound of the formula (I): wherein R1 and R2 independently represent hydrogen or (C1-C6)alkyl or the like; R3 and R4 independently represent hydrogen or (C1-C3)alkyl; n represents 1 or 2; A represents phenyl or a monocyclic heteroaryl having from 5 to 6 atoms or the like; and R5 and R6 each independently represent halogen, (C1-C6)alkyl, cyano, hydroxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl and (C1-C6)alkylsulfonyl; or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  该发明提供了一种具有以下结构的化合物（I）：其中R1和R2分别代表氢或（C1-C6）烷基等；R3和R4分别代表氢或（C1-C3）烷基；n代表1或2；A代表苯基或具有5至6个原子的单环杂环烷基等；R5和R6各自独立地代表卤素，（C1-C6）烷基，氰基，羟基，羟基（C1-C6）烷基，（C1-C6）氧基，卤代（C1-C6）烷基，（C1-C6）硫代烷基，（C1-C6）磺酰基或（C1-C6）磺酰基；或该化合物的药学上可接受的酯，或其药学上可接受的盐。这些化合物对于治疗由VR1受体过度活化引起的疾病状况，如疼痛等，在哺乳动物中很有用。该发明还提供了一种包含上述化合物的药物组合物。
• Antibacterial benzoic acid derivatives
  申请人：——

  公开号：US20040110802A1

  公开（公告）日：2004-06-10

  The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

  这项发明提供了抗微生物药剂及其使用方法，用于哺乳动物的消毒、卫生、防腐、消毒和治疗感染。
• SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS
  申请人：Meier Heinrich

  公开号：US20130005704A1

  公开（公告）日：2013-01-03

  The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

  本申请涉及新型取代的4-芳基咪唑-2-酮和5-芳基-1,2,4-三唑酮，其生产过程，其单独或联合用于治疗和/或预防疾病的用途以及用于生产用于治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病。
• Pharmacologically active pyrrole and pyrazole derivatives
  申请人：FISONS plc

  公开号：EP0230110A1

  公开（公告）日：1987-07-29

  There are described compounds of formula I, wherein either one of Y and Z (which may be the same or different) represents CH, CR2 or C-COOR21, in which R2 represents alkyl C 1 to C6 optionally substituted by halogen, hydroxy, amino, isothioureido or a group R5COO- in which R5 represents alkyl C 1 to C6, R2 being optionally interrupted by O or S, and R21 represents alkyl C 1 to C6, and the other one of Y and Z represents CR2 or C-COOR21, or one of Y and Z represents N and the other CH, CR2 or C-COOR21, R4 represents Ar1-B-(W)x, in which W represents C=O, S, SO, SO2 or C=N-OH, x represents 0 or 1, B represents a single bond or (CH2)p in which p represents 1 or 2, the group (CH2)p being optionally substituted by alkyl C1 to Ar1 represents phenyl, naphthyl or benzofurazanyl, Ar1 being optionally substituted by one or more of X, CX3, OCHnX3-n, hydroxy, alkyl C 1 to C6, Oalkyl C 1 to C6, nitro, amino, carboxy, -SCH2Ar2, -OCH2Ar2 or -OCOAr2 in which X represents halogen, n represents 0,1, 2 or 3, and Ar2 represents phenyl or phenyl substituted by hydroxy, halogen, alkyl C 1 to C6 or Oalkyl C 1 to C6, and R3 and R1 are as defined in the specification. There are also described processes for the preparation of compounds of formula I and pharmaceutical, eg cardiovascular, compositions containing them.

  所述化合物为式 I、 式中 Y和Z（可以相同或不同）中的一个代表CH、CR2或C-COOR21，其中R2代表任选被卤素、羟基、氨基、异硫脲基或基团R5COO-取代的C 1至C6烷基，其中R5代表C 1至C6烷基，R2任选被O或S打断，R21代表C 1至C6烷基，Y和Z中的另一个代表CR2或C-COOR21、 或 Y 和 Z 中的一个代表 N，另一个代表 CH、CR2 或 C-COOR21、 R4 代表 Ar1-B-(W)x，其中 W 代表 C=O、S、SO、SO2 或 C=N-OH、 x 代表 0 或 1、 B 代表单键或 (CH2)p，其中 p 代表 1 或 2，(CH2)p 组可选择被烷基 C1 至 C2 取代。 Ar1 代表苯基、萘基或苯并呋喃基，Ar1 可任选被一个或多个 X、CX3、OCHnX3-n、羟基、C 1 至 C6 烷基、C 1 至 C6 氧代烷基、硝基、氨基、羧基、-SCH2Ar2、-OCH2Ar2 或 -OCOAr2 取代，其中 X 代表卤素 n 代表 0、1、2 或 3，以及 Ar2 代表苯基或被羟基、卤素、C 1 至 C6 烷基或 C 1 至 C6 O 烷基取代的苯基，以及 R3 和 R1 如说明书中所定义。 还描述了制备式 I 化合物和含有它们的药物（如心血管）组合物的工艺。